Users Discontinuing Weight-Loss Injections Regain Pounds at a Quadrupled Rate Than Dieters

Fresh analysis suggests that individuals who come off new GLP-1 drugs like Wegovy and Mounjaro can put back on reduced body mass much more quickly than those who stop conventional diet and exercise programs.

Research printed in a leading health publication points out that while overweight people frequently drop about a fifth of their total mass while using the jabs, the mass returns at an estimated rate of nearly a kilo each month after stopping.

"Individuals purchasing these drugs need to be aware of the potential of fast rebound weight gain when the treatment ends," warns expert Dr. Susan Jebb.

This pace of recovery suggests a return to pre-treatment mass in about 18 months.

Comparing Therapies

The analysis, which looked at 37 of trials involving over 9,000 of patients, contrasted the outcomes of GLP-1 agonists with conventional dieting.

The team point out that individuals who shed pounds through lifestyle changes alone typically have a less rapid creep back—perhaps 100 grams monthly—after stopping.

Understanding the Rapid Rebound

Experts suggest the mode of action of the drugs is key to understanding the accelerated regain.

The injections imitate a natural hormone called glucagon-like peptide-1, which moderates appetite.

"Artificially providing the hormone concentrations several times higher than the body's typical production might result in the body to produce less of its endogenous hormone, and may also reduce responsiveness to its actions," explained Dr. Adam Collins, a nutrition specialist.

"Stopping of this GLP-1 'fix' leads to appetite is no longer kept in check, making binge eating far more likely."

A Chronic Issue?

Health authorities suggest the injections for people with weight-linked health risks, accompanied by recommended diet and exercise modifications.

Professionals say that, due to the high risk of relapse, the therapy should be considered life-long.

This opinion is echoed by drug manufacturers, who state that the findings "highlight the persistent nature of obesity," similar to managing diseases like high blood pressure.

Patient Testimonies

Individuals who have discontinued the medication report a powerful resurgence of appetite.

"I experienced something flipping and I was suddenly starving," recalled an individual.

This challenge is compounded if users have not developed sustainable dietary or behavioural changes during treatment.

Significant Interest

Survey data indicate that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with demand remaining high.

• Adoption is higher among females compared to men.
• The 40s and 50s age group shows the highest level of interest.
• A large proportion access the medications through private healthcare rather than the NHS.

In conclusion, clinicians stress that while these medications are potent tools for shedding pounds, they are not a magic fix and lasting health benefits relies on integrated lifestyle support.